Advantage Alpha Capital Partners LP purchased a new position in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 23,617 shares of the medical instruments supplier’s stock, valued at approximately $64,000.
Several other institutional investors and hedge funds have also recently bought and sold shares of HBIO. GSA Capital Partners LLP acquired a new position in shares of Harvard Bioscience during the 3rd quarter worth approximately $30,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Harvard Bioscience in the second quarter valued at $31,000. SG Americas Securities LLC bought a new position in shares of Harvard Bioscience in the third quarter valued at about $36,000. Avior Wealth Management LLC lifted its stake in shares of Harvard Bioscience by 1,118.1% during the 3rd quarter. Avior Wealth Management LLC now owns 14,569 shares of the medical instruments supplier’s stock worth $39,000 after buying an additional 13,373 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Harvard Bioscience during the 2nd quarter worth about $40,000. Institutional investors own 80.87% of the company’s stock.
Harvard Bioscience Stock Performance
Shares of HBIO opened at $2.19 on Wednesday. The firm’s 50-day simple moving average is $2.43 and its 200 day simple moving average is $2.81. The company has a current ratio of 2.06, a quick ratio of 0.91 and a debt-to-equity ratio of 0.52. Harvard Bioscience, Inc. has a 52 week low of $1.99 and a 52 week high of $5.56.
Harvard Bioscience Profile
Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.
Recommended Stories
- Five stocks we like better than Harvard Bioscience
- The How And Why of Investing in Oil Stocks
- Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor
- Election Stocks: How Elections Affect the Stock Market
- Why Warren Buffett Is Selling: A Look at His Latest Market Moves
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Why Amazon Shares May Never Trade Below $200 Again
Want to see what other hedge funds are holding HBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harvard Bioscience, Inc. (NASDAQ:HBIO – Free Report).
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.